BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:N-acetylcysteine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of N-acetylcysteine\, from ClinicalTrials.go
 v estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07414212-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:N-acetylcysteine: Phase 1/2 readout est. (NCT07414212)
DESCRIPTION:N-acetylcysteine\, phase 1/2.\nStudy: Evaluation of the Combine
 d Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotro
 phic Lateral Sclerosis (ALS)\nEstimated primary completion: 25 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0741
 4212
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245095-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07245095)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Premedication With N-acetyl
 cysteine and Simethicone to Improve Mucosal Visualization in Elective Uppe
 r Endoscopy\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07245095
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377410-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:N-acetylcysteine: Phase na readout est. (NCT06377410)
DESCRIPTION:N-acetylcysteine\, phase na.\nStudy: Efficacy & Safety of Dry P
 owder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients\nEstimate
 d primary completion: 30 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06377410
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04520139-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:N-acetylcysteine: Phase 1/2 readout est. (NCT04520139)
DESCRIPTION:N-acetylcysteine\, phase 1/2.\nStudy: Effect of NAC on Preventi
 ng Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04520139
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04677816-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT04677816)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Impact of Vitamin D Supplem
 entation on the Rate of Pathologic Complete Response in Vitamin D Deficien
 t Patients\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04677816
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03652753-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:N-acetylcysteine: Phase 4 readout est. (NCT03652753)
DESCRIPTION:N-acetylcysteine\, phase 4.\nStudy: Pilon Fracture With Intra-a
 rticular Injection of N-Acetylcysteine (Pilon NAC)\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/n-acetylcysteine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03652753
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05796401-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT05796401)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Efficiency of a Composite P
 ersonalised Care on Functional Outcome in Early Psychosis\nEstimated prima
 ry completion: 15 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05796401
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07634991-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:N-acetylcysteine: Phase 4 readout est. (NCT07634991)
DESCRIPTION:N-acetylcysteine\, phase 4.\nStudy: To Evaluate the Efficacy an
 d Safety of N-acetyl Cysteine Administration in Patients With Diabetic Ret
 inopathy\nEstimated primary completion: 30 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07634991
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07279610-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT07279610)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: N-Acetylcysteine as Thera
 py for Transplantation- Associated Thrombotic Microangiopathy\nEstimated p
 rimary completion: 31 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07279610
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227649-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07227649)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: NAC-REPAIR for Post-surgica
 l Pain\nEstimated primary completion: 15 January 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07227649
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05122559-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT05122559)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Neuroprotection With N-acet
 yl Cysteine for Patients With Progressive Multiple Sclerosis\nEstimated pr
 imary completion: February 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05122559
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00775476-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT00775476)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Treatment of Systemic Lupus
  Erythematosus (SLE) With N-acetylcysteine\nEstimated primary completion: 
 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-acet
 ylcysteine#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT00775476
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02750319-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT02750319)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Amiodarone and N-Acetylcyst
 eine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic
  Surgery\nEstimated primary completion: April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT02750319
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890507-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT06890507)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: The Anti-Anginal Effects of
  N-Acetylcysteine (NAC) in Patients with Angina and Non-Obstructive Corona
 ry Arteries (ANOCA)\nEstimated primary completion: 1 April 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06890507
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07049952-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT07049952)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: BabySTrong II taVNS Feedi
 ng Trial\nEstimated primary completion: 1 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07049952
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04440280-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT04440280)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Targeting Reactive Oxygen S
 pecies Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dys
 trophy\nEstimated primary completion: 29 April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04440280
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542161-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT04542161)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Assessment of N-Acetylcyste
 ine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome\nEst
 imated primary completion: 30 April 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04542161
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156786-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT07156786)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: N-Acetylcysteine Roles in
  Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecu
 le-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemoth
 erapy: A Randomized Placebo-Controlled Trial\nEstimated primary completion
 : 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-ac
 etylcysteine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07156786
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04374461-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT04374461)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: A Study of N-acetylcysteine
  in Patients With COVID-19 Infection\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0437
 4461
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381897-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT04381897)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Use of N-Acetylcysteine in 
 the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de La
 nge Syndrome\nEstimated primary completion: 1 May 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04381897
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117630-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07117630)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: An Open-Label\, Bayesian Ad
 aptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After P
 rogression on Standard Therapy\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07117630
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803952-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:N-acetylcysteine: Phase 1/2 readout est. (NCT07803952)
DESCRIPTION:N-acetylcysteine\, phase 1/2.\nStudy: N-Acetylcysteine in the M
 anagement of Spontaneous Bacterial Peritonitis\nEstimated primary completi
 on: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-ac
 etylcysteine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07803952
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06811675-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:N-acetylcysteine: Phase 4 readout est. (NCT06811675)
DESCRIPTION:N-acetylcysteine\, phase 4.\nStudy: The Efficacy of Dexamethaso
 ne in Combination With N-acetylcysteine in Preventing Neurocognitive Seque
 lae Due to Carbon Monoxide Poisoning\nEstimated primary completion: 30 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-acetylcyste
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06811675
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387666-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:N-acetylcysteine: Phase 1 readout est. (NCT07387666)
DESCRIPTION:N-acetylcysteine\, phase 1.\nStudy: Imaging Acetadote Metabolis
 m in Glioblastoma\nEstimated primary completion: 1 July 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07387666
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03241732-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270708
DTEND;VALUE=DATE:20270709
SUMMARY:N-acetylcysteine: Phase na readout est. (NCT03241732)
DESCRIPTION:N-acetylcysteine\, phase na.\nStudy: PET-MRI in Chronic Traumat
 ic Brain Injury (CTBI)\nEstimated primary completion: 8 July 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03241732
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03032601-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270708
DTEND;VALUE=DATE:20270709
SUMMARY:N-acetylcysteine: Phase na readout est. (NCT03032601)
DESCRIPTION:N-acetylcysteine\, phase na.\nStudy: Physiological Effects of N
 -Acetyl Cysteine in Patients With Multiple Sclerosis\nEstimated primary co
 mpletion: 8 July 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/n-acetylcysteine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03032601
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06546475-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:N-acetylcysteine: Phase 4 readout est. (NCT06546475)
DESCRIPTION:N-acetylcysteine\, phase 4.\nStudy: A Pilot Trial of Tapering A
 ntipsychotics for Patients in Remitted Psychosis Co-administering With N-A
 cetylcysteine\nEstimated primary completion: 31 July 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06546475
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917338-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07917338)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Oral N-Acetylcysteine on Di
 abetic Macular Edema\nEstimated primary completion: 1 October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07917338
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081479-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20271021
DTEND;VALUE=DATE:20271022
SUMMARY:N-acetylcysteine: Phase 1 readout est. (NCT05081479)
DESCRIPTION:N-acetylcysteine\, phase 1.\nStudy: A Study of N-Acetylcysteine
  (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma\nEstimated pri
 mary completion: 21 October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05081479
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03900988-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT03900988)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Intravenous N-acetylcystein
 e and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza
  and Pneumonia\nEstimated primary completion: 31 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03900988
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662525-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:N-acetylcysteine: Phase na readout est. (NCT07662525)
DESCRIPTION:N-acetylcysteine\, phase na.\nStudy: Atorvastatin Combined With
  NAC Plus Romiplostim for Management of ITP\nEstimated primary completion:
  30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-
 acetylcysteine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07662525
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06909799-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:N-acetylcysteine: Phase na readout est. (NCT06909799)
DESCRIPTION:N-acetylcysteine\, phase na.\nStudy: A Confirmatory Trial of Ad
 junctive NAC to Prevent Post Tuberculosis Lung Disease\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06909799
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05664789-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT05664789)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: Targeting the Neurobiolog
 y of RRB in Autism Using N-acetylcysteine: Trial\nEstimated primary comple
 tion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/n-acetylcysteine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05664789
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07273071-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:N-acetylcysteine: Phase 4 readout est. (NCT07273071)
DESCRIPTION:N-acetylcysteine\, phase 4.\nStudy: Individualized Multiplex Pa
 thophysiological Treatment of Severe Acute Infections: N-Acetylcysteine\nE
 stimated primary completion: February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07273071
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986318-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT05986318)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Reducing Respiratory Sympto
 ms of Pulmonary Irradiation in Interstitial Lung Disease\nEstimated primar
 y completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/n-acetylcysteine#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05986318
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939841-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07939841)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: N-Acetylcysteine (NAC) in P
 rimary Sclerosing Cholangitis (PSC)\nEstimated primary completion: 1 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/n-acetylcystein
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 939841
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04278898-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT04278898)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Targeting the Neurobiology 
 of RRB in Autism Using N-acetylcysteine: Single-dose\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/n-acetylcysteine#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04278898
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05494398-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:N-acetylcysteine: Phase 2/3 readout est. (NCT05494398)
DESCRIPTION:N-acetylcysteine\, phase 2/3.\nStudy: Targeting the Neurobiolog
 y of RRB in Autism Using N-acetylcysteine: Open Label\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/n-acetylcysteine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05494398
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083480-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:N-acetylcysteine: Phase 4 readout est. (NCT06083480)
DESCRIPTION:N-acetylcysteine\, phase 4.\nStudy: Reducing Perioperative Oxid
 ative Stress to Prevent Postoperative Chronic Pain Following Total Knee Ar
 throplasty\nEstimated primary completion: September 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06083480
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07737262-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT07737262)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Prophylactic NAC to Improve
  Platelet Engraftment After Haploidentical Transplantation in Severe Aplas
 tic Anemia Patients\nEstimated primary completion: 30 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07737262
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875322-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:N-acetylcysteine: Phase 1 readout est. (NCT07875322)
DESCRIPTION:N-acetylcysteine\, phase 1.\nStudy: Silymarin Versus N-Acetylcy
 steine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver 
 Injury.\nEstimated primary completion: 1 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07875322
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759895-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07759895)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: Combination Therapy of Defe
 riprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophren
 ia\nEstimated primary completion: December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07759895
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898839-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07898839)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: FEAST and HOPE: Redox PSC P
 ilot Study\nEstimated primary completion: December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07898839
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07869342-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:N-acetylcysteine: Phase na readout est. (NCT07869342)
DESCRIPTION:N-acetylcysteine\, phase na.\nStudy: NAC for Hematopoietic Reco
 very in Low/Intermediate-Risk AML After CR: A Randomized Controlled Study\
 nEstimated primary completion: 31 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07869342
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05537220-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT05537220)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Oral N-acetylcysteine for R
 etinitis Pigmentosa\nEstimated primary completion: May 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05537220
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290530-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT07290530)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: 24-Month Trial of NPI-001 f
 or the Preservation of Photoreceptors in Retinitis Pigmentosa Associated W
 ith Usher Syndrome\nEstimated primary completion: July 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07290530
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03999021-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:N-acetylcysteine: Phase 1 readout est. (NCT03999021)
DESCRIPTION:N-acetylcysteine\, phase 1.\nStudy: FIGHT-RP 1 Extension Study\
 nEstimated primary completion: December 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03999021
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323446-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:N-acetylcysteine: Phase 1 readout est. (NCT07323446)
DESCRIPTION:N-acetylcysteine\, phase 1.\nStudy: The MIND Study: The MGH/MIT
  Investigation of NAC on Dysregulation\nEstimated primary completion: 1 Ja
 nuary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-acetylc
 ysteine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07323446
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464886-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT07464886)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Prefrontal Glutamatergic Mo
 dulation by NAC and MBCT for Depression in Youth\nEstimated primary comple
 tion: March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n-a
 cetylcysteine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07464886
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543458-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT07543458)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: Therapeutics for Moderate a
 nd Severe Dengue\nEstimated primary completion: 31 July 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07543458
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06260566-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:N-acetylcysteine: Phase 1 readout est. (NCT06260566)
DESCRIPTION:N-acetylcysteine\, phase 1.\nStudy: Tolerability of Enteral NAC
  in Infants\nEstimated primary completion: October 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06260566
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136987-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:N-acetylcysteine: Phase 3 readout est. (NCT07136987)
DESCRIPTION:N-acetylcysteine\, phase 3.\nStudy: A Trial of 2 Disease-Modify
 ing Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Re
 covery\nEstimated primary completion: January 2031. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07136987
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913542-3863@assetmemo.bio
DTSTAMP:20261121T004953Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:N-acetylcysteine: Phase 2 readout est. (NCT07913542)
DESCRIPTION:N-acetylcysteine\, phase 2.\nStudy: N-Acetylcysteine for Bipola
 r and Alcohol Use Disorders\nEstimated primary completion: 31 August 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/n-acetylcysteine#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0791354
 2
URL:https://assetmemo.bio/drug/n-acetylcysteine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
